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1. Introduction 
Human schistosomiasis, which is caused by trematodes of the genus Schistosoma, is 
considered one of the most prevalent and debilitating neglected diseases in tropical and 
subtropical areas, being endemic to approximately 76 countries and territories and affecting 
more than 207 million people worldwide. About 800 million people live in infection risk 
areas and 280,000 die every year due to this disease (Engels et al., 2002, Steinmann et al., 
2006).  
There are six main species of Schistosoma that can infect humans: S. mansoni, S. hematobium, 
S. japonicum, S. intercalatum, S. mekongi and S. malayensis. Among these, only S. mansoni is 
found in Brazil.  
S. mansoni schistosomiasis was probably brought to Brazil by the Atlantic slave trade. 
Afterwards, migration flows spread the disease from the shore to the interior of the country, 
including areas containing its intermediate hosts, planorbides of the genus Biomphalaria 
(Paraense, 1986, Coura & Amaral, 2004). According to Paraense (1966, 1981), ten species and 
one subspecies of Biomphalaria can be found in the country, three of them being natural 
intermediate hosts (B. glabrata, B. tenagophila, B. straminea) and two having already been 
experimentally infected (B. amazonica and B. peregrina).  
The life cycle of S. mansoni consists of an asexual reproduction stage in the intermediate 
hosts and a sexual reproduction stage in the definite ones. Under favourable conditions, it 
lasts 80 days (Katz & Almeida, 2003, Ministério da Saúde, 2005). 
Nowadays, there are 25 million people living in endemic areas in Brazil, and 4 to 6 million 
are infected. It is the most affected country in the Americas (Lambertucci, 2010, World 
Health Organization [WHO], 2010). According to data provided by Brazil’s Ministry of 
Health, there are cases of the disease in 19 states, from Rio Grande do Norte to Bahia and in 
the interior of Espírito Santo and Minas Gerais (Ministério da Saúde, 2005). Figure 1 shows 
the distribution of S. mansoni schistosomiasis in Brazil. 
A major problem in countries where schistosomiasis is endemic is the control of the disease. 
In this regard, isolated or combined measures could be taken, such as the control of the 
intermediate hosts using molluscicides, improvement of basic sanitation and water supply 
conditions, sanitary education of exposed populations, individual or mass treatment in 
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high-prevalence areas, individual protection against the penetration of cercariae, and 
development of a vaccine (Coura & Amaral 2004). 
 
 
Fig. 1. Distribution of S. mansoni schistosomiasis in Brazil. Source: Ministério da Saúde 
(2005). 
However, such control measures have many drawbacks: the wide dissemination of the 
intermediate hosts, their defence mechanisms against molluscicides, as well as the high costs 
and low efficiency of that sort of control, the high costs associated with the implementation 
of adequate sanitary and water supply conditions and the intense contact of rural 
population with contaminated fresh water, the long time needed for sanitary education, 
individual or mass treatments can be effective in reducing the morbidity, but they do not 
prevent reinfections, and patients can develop tolerance and resistance to them, individual 
protection is unlikely, except for specific groups of exposed people, finally, at the present 
moment there is no effective vaccine in the treatment for schistosomiasis (Coura & Amaral, 
2004). 
Despite the fact that the distribution of schistosomiasis has changed along the time, the 
number of infected people or people at risk of infection has not changed. Not even the 
efforts carried out for more than a century to control schistosomiasis by means of 
schistosomicidal drugs have prevented it from being one of the most prevalent diseases in 
the world (King, 2009). Albeit all the research conducted so far, there are no effective 
vaccines against parasitic diseases. Therefore, medication treatment is still the most efficient 
method (Date et al., 2007). 
The treatment for S. mansoni schistosomiasis is based on the use of praziquantel, a low-cost 
anthelmintic highly effective against all Schistosoma species that may cause infection in 
humans. Despite its benefits, some deficiences have been reported. As a result, it is 
necessary to develop new effective schistosomicidal drugs. 
Regarding S. mansoni schistosomiasis, the World Health Organisation (WHO) points out the 
need for permanent research on the development of a vaccine (WHO, 1998). Furthermore, 
current drugs need to be improved, or new ones should be developed. Nevertheless, the 
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cost for developing safe and effective drugs is extremely high, which leads to a dim 
perspective on the introduction of new schistosomicides (Cioli et al., 1995). As a result, 
research with medicinal plants constitutes a very viable alternative.  
In this scenario, several studies and researches on natural bioactive products extracted from 
plants and used against schistosomiasis have been carried out in the search for a new 
medicine that can replace praziquantel or complement it (Xiao & Catto, 1989, Molgaard et 
al., 2001, Mahmoud et al., 2002, Mohamed et al., 2005, Shaohong et al., 2005, Penido et al., 
2008, Moraes et al., 2010). 
Taking into account the great variety of plants that haven’t yet been therapeutically studied 
to combat S. mansoni schistosomiasis, in recent years our research group started a  
multidisciplinary project to perform in vitro screening of extracts from native and exotic 
plants commonly cultivated in Brazil. 
2. Chemotherapy against schistosomiasis 
It is believed that the use of chemotherapy against schistosomiasis started with 
Christopherson (1918), who reported a successful treatment for the urinary form of the 
disease (caused by S. haematobium) with tartar emetic.  After that, several other antimony 
compounds were introduced for clinical use (Cioli et al., 1995, Parise-Filho & Silveira, 2001), 
and they were the most used medicines until the Second World War (Brindley, 1994). 
However, despite having been the basis of the treatment for schistosomiasis for around 50 
years and having been effective against S. mansoni, S. haematobium and S. japonicum, the 
clinical use of antimony compounds was suspended on account of their severe side and 
toxic effects and patients’ low tolerance to them (Cunha, 1982, Cioli et al., 1995, Silva, 1997, 
Cioli, 1998, Novaes et al., 1999).   
Before antimony compounds fell into disuse, researches carried out in the 1920’s showed 
activity of emetine and 2,3-dehydroemetine, which were used in the treatment for 
amoebiasis, against S. japonicum. Although emetine has shown a relatively good efficiency, 
the concentrations needed for activity against S. japonicum were two times higher than the 
required in the treatment for amoebiasis, reaching the toxicity limit.  On the other hand, 2,3-
dehydroemetine, in spite of being less toxic and having light side effects in comparison with 
emetine, fell into disuse because of its complicated administration (Blanc & Nosny, 1968, 
Cioli et al., 1995). 
After the Second World War, new drugs were produced, and they were less toxic, more 
active, free from metals and orally administered (Cunha, 1982, Cioli et al., 1995). Lucanthone 
(1-{[2-(diethylamino)ethyl]amino}-4-methyl-9H-thioxanthen-9-one), or Miracil D, described 
for the first time in 1932, was the first orally administered schistosomicidal drug introduced 
in medical practice, being effective against both S. mansoni and S. haematobium. Its side 
effects were usually limited to nausea and vomiting, but severe effects on the heart and 
central nervous system were later reported (Kikuth & Gonnert, 1948). 
In 1955, an organophosphate insecticide (2.2,2-trichloro-1-hydroxyenthyl dimethyl 
phosphonate) was introduced under the general name trichlorphon (Lorenz et al., 1955), 
later changed to metrifonate. Then, in 1962, the possibility of extending its use to helminths 
came into consideration, and preliminary studies in humans provided evidence of 
therapeutic activity against schistosomiasis, ancylostomiasis, ascariasis, trichuriasis and 
onchocerciasis (Cerf et al., 1962, Davis & Bailey, 1969, Salazar et al., 1969). However, this 
compound has only proven effective in the treatment for urinary schistosomiasis (Jewsbury 
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et al., 1977). Therefore, at the present day metrifonate (Bilarcil) is still used in such 
treatment, but it has to be administered in three doses, and that is its main drawback (Korte 
et al., 1986, WHO, 1993, Cioli et al., 1995,  Berge et al., 2011). 
At the beginning of the 1960’s, it was reported that a broad-spectrum antimicrobial called 
nitrofuran, along its derivatives, had shown schistosomicide activity, more specifically, anti-
S. japonicum effect. Nonetheless, its suboptimal activity, high toxicity, and carcinogenic and 
mutagenic effects led to its use being stopped, and the same happened to its derivatives, 
some of which didn’t even come to be used in the treatment for human schistosomiasis 
(Werbel, 1970, Robinson et al., 1970, Hulbert et al., 1973). 
A very important moment in the therapeutics of schistosomiasis came after the introduction 
of niridazole (1-(5-nitro-2-thiazolil)imidazolidin-2-one) in 1964 (Lambert & Stauffer, 1964) 
and hycanthone (1-N-b-diethyl-amino-ethyl-amino-4-(hydroxymethyl)-9-thioxanthenone) in 
1965 (Rosi et al., 1965). Niridazole (Ambilhar) showed low activity against S. japonicum, 
moderate activity against S. mansoni and very high activity against S. haematobium, whereas 
hycanthone (Etrenol), the main metabolite of lucanthone, proved effective against S. 
mansoni, S. haematobium and S. rodhaini. However, these drugs had some issues, such as the 
number of doses and various severe side effects (high toxicity in the central nervous system, 
kidneys and liver, in addition to mutagenic, carcinogenic and teratogenic effects). 
Furthermore, they were not considered safe enough for being used in large scale in endemic 
regions. Consequently, they were no longer used in the medication therapy of 
schistosomiasis (Fontanilles, 1969, Cioli et al., 1995).   
At the end of the 1960’s, a series of 2-aminomethyl-tetra-hydroquinoline derivatives with 
schistosomicidal activity were described, the most promising being 2-N-
isopropylaminomethyl-7-nitro-l,2,3,4-tetrahydroquinoline, named UK-3883. The 
hydroxylation of the 6-methyl group by Aspergillus sclerotiorum generated UK-4271, later 
called oxamniquine (Mansil/Vansil) and described for the first time by Richards and Foster 
in 1969 (Cioli et al., 1993, 1995).  
Preclinical assays showed the schistosomicide potencial of oxamniquine against S. mansoni, 
especially males (Foster & Cheetham, 1973).  
Clinical assays carried out in Brazil with an orally administered single dose of 15 to 20 
mg/kg have shown cure rates up to 90%, as well as good tolerance by patients. These results 
allowed oxamniquine to be extensively used, and it was included in Brazilian programmes 
for the control of S. mansoni schistosomiasis (Almeida-Machado, 1982, Foster, 1987, Cioli et 
al., 1993).  
Further studies indicated some disadvantages in the use of oxamniquine, though. Since this 
drug has no cell specificity, which results in undesired peripheral toxicity, there are some 
side effects on the central nervous system (Davis, 1993, Soyez et al., 1996). It was also 
observed that oxamniquine showed low activity in the period between the 3rd and the 9th 
week of infection, which coincided with the egg production stage (Jordan et al., 1993, 
Frézard & Melo, 1997). Moreover, there were reports of pacients infected with S. mansoni  
who were resistent to the treatment (Cioli et al., 1992). 
At the beginning of the 1970’s, pyrazinoisoquinoline derivatives were tested as antiparasitic 
drugs (Andrews, 1981). After many compounds were synthesised, 2-cyclohexylcarbonyl-
1,2,3,6,7,1lb-hexahydro-4H-pyrazino[2,1-a]isoquinoline-4-one, first called EMBAY-8440 and 
then praziquantel (Biltricide/Cysticide/Cesol/Distocid/Pyquiton), was considered the 
most promising (Cioli et al., 1995).  Discovered in 1975 (Andrews et al., 1983, Day et al., 
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1992), this drug was initially used against cestodes and limited to veterinary cases (Thomas 
& Gonnert, 1975).   
The first studies with animals infected with Schistosoma sp. were performed in 1977, when 
schistosomicidal activity was detected (Gonnert & Andrews, 1977) and attention was drawn 
to the large variety of possibilities offered by worms of that genus. Further studies reported 
activity of praziquantel against S. haematobium, S. japonicum, S. intercalatum and S. matheei, 
other species of trematodes (Opisthorchis sinensis, O. viverrini, Paragonimus spp., Fasciolopsis 
buski, Heterophyes heterophyes and Metagonimus yokogawaii) and cestodes (Taenia solium, T. 
saginata, Hymenolepis nana, H. diminuta, Diphyllobotrium latum and D. pacificum) (Webbe & 
James, 1977, Wegner, 1984, Bouree, 1991, Utzinger et al., 2003, Shuhua, 2005, Jeziorski & 
Greenberg, 2006, Shaohong et al., 2005). 
Preclinical assays have also proven the efficiency of praziquantel in the treatment for 5-6-
week infections, but failures were reported in cases of 1 to 5-week infections (Gonnet & 
Andrews, 1977, Webbe, 1977, Xiao et al., 1985, Sabah et al., 1986).  
The first clinical studies took place in 1978 in cooperation with WHO, in endemic regions for 
S. mansoni, S. haematobium, S. japonicum and S. intercalatum (Katz et al., 1979, Davis et al., 
1979, Ishizaki et al., 1979). In 1984, cure rates of 75% to 85% were reported for S. 
haematobium, 63% to 85% for S. mansoni, 80% to 90% for S. japonicum, 89% for S. intercalatum, 
and 60% to 80% for simultaneous infections with S. mansoni and S. haematobium (Wegner, 
1984). It was also found out that praziquantel was well tolerated by patients of all ages with 
different clinical forms of schistosomiasis (Frohberg, 1984, Bassily et al., 1985), having light 
side effects on them (Cioli et al., 1995). Other studies indicated low toxicity and no 
mutagenic risks (Frohberg, 1984, Kramers et al., 1991). 
Those screenings clearly established praziquantel as the drug of choice in the treatment for 
schistosomiasis (Cioli & Pica-Mattoccia, 2002). In addition, it was the first anthelmintic to 
fulfil the requirements of WHO (Silva et al., 2005).  
After the development of praziquantel, there was little progress in the therapeutics of S. 
mansoni schistosomiasis.  
In 1976, Striebel described the use of amoscanate (4-isothiocyanato-4’-nitrodiphenylamine) 
against helminthic diseases. At that time its wide activity range was confirmed, as it was 
used against most Schistosoma species, filariae and gastrointestinal nematodes (Bueding et 
al., 1976). Amoscanate was tested in humans infected with S. japonicum, and the cure rates 
were as high as 92%. However, this drug fell into disuse in view of hepatotoxicity (Hubei 
Nithiocyaminum Coodination Research Group, 1980, Cioli et al., 1995).  
Also in 1976, a dithiolethione derivative called oltipraz (Barrau et al., 1977), active against S. 
mansoni, S. intercalatum and S. haematobium (Leroy et al., 1978, Gentilini et al., 1980, Katz et 
al., 1984), was synthesised. Preclinical assays confirmed the elimination of S. mansoni 
(Bueding et al., 1982), and clinical assays showed cure rates between 80% and 95% for this 
species. Photo-onycholysis was the most severe side effect observed, leading to the 
suspension of the drug in 1984 (Cioli et al., 1995).  
Still in 1976, Nelson and Pellegrino (1976) described the schistosomicidal activity of 
alkylaminoalkanethio-sulfuric acids for the first time. Preclinical assays with S. mansoni 
provided evidence of preferential activity against adult females (Penido et al., 1999), but so 
far no clinical assays have been carried out.  
In 1978, screening of benzodiazepine derivatives showed that some of the compounds of 
this group have strong schistosomicidal activity, in particular  (+)-5-(-o-chlorophenyl)-1,3-
dihydro-3-methyl-7-nitro-2H-1,4-benzodiazepine-2-one, which was named  Ro 11-3128 
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(Stohler, 1978). Preclinical studies proved it to be effective against S. mansoni and S. 
haematobium (Brickle & Andrews, 1995) and clinical studies confirmed its schistosomicidal 
activity, but some side effects, including strong sedative effect, have discouraged its 
development (Pax et al., 1978, Baard et al., 1979). 
In the 1980’s, derivatives of artemisinin (which is extracted from Artemisia annua) were used 
as anti-Schistosoma sp. for the first time by the Chineses, who demonstrated that the 
administration of this compound in animals experimentally infected with  S. japonicum  
reduced their worm burden (Chen et al., 1980). 
Such derivatives, which include arteether, artemisone and artelinic acid, among others, have 
been extensively used in the control of malaria. They are generically known as artemisinins 
and were developed in the 1970’s (Krishna et al., 2008).   
In 1982, it was shown that larval stages of S. japonicum were susceptible to artemisinins (Le 
et al., 1982). Further studies confirmed the schistosomicidal activity of both artesunate and 
artemether, the latter reaching cure rates of 99% (Le et al., 1983, Le et al., 1982). In 1984, such 
derivatives were proved effective against juvenile stages of Schistosoma sp., when treatments 
carried out with praziquantel fail, thus both artemether and artesunate are potential 
prophylactic drugs  for schistosomiasis (Yue et al., 1984, Lu et al., 2010). Other studies 
extended the activity of artemisinin derivatives to other Schistosoma sp. that infect humans. 
In particular, assays carried out in Brazil in 1991 showed reduction of parasite burden in 
mice infected with S. mansoni and treated with artemether (Araújo et al., 1991). Since then, 
outstanding progress has been made in the study of anti-Schistosoma sp. activity, especially 
with artemether and artesunate (Cioli & Pica-Mattoccia, 2002, Xiao et al., 2000, Lu et al., 
2010). 
Clinical assays with artemether have already been carried out in Ivory Cost (Africa) and 
have shown less incidence of infections caused by S. mansoni and S. japonicum (Utzinger et 
al., 2003, Xiao et al., 2000). In regard to toxicity, it was proved by clinical tests that 
artemisinins are well tolerated when administered orally (Notprasert et al., 2002). 
In some regions of the globe endemic areas for malaria and schistosomiasis overlap, and it is 
suggested that in such regions the use of artemisinin, intending to treat malaria cases, can 
reduce the morbidity rate of endemic schistosomiasis (Lescano et al., 2004). 
After the first studies on the schistosomicidal activity of artemisinins, another drug had its 
anti-Schistosoma sp. activity researched, namely cyclosporin A, whose anthelmintic activity 
was discovered by Bueding et al. in 1981. Reduction in the number of worms and 
suppression of granuloma formation were noted in mice infected with S. mansoni, as well as 
prophylactic effect against this worm (Bout et al., 1986).  
In 1984, a series of acridine derivatives showed schistosomicidal activity. In vivo studies 
demonstrated their efficiency against S. mansoni, S. japonicum and S. haematobium (Stohler & 
Montanova, 1984). Assays carried out in primates showed cure of the host with the use of 
some of these derivatives, RO 15-5458/000 being one of them (Coelho & Pererira, 1991). It is 
a fact that acridine derivatives are an important class of compounds for the development of 
new drugs with anticonvulsant, antidepressant, analgesic, anti-inflammatory, antiplatelet, 
antimalarial, antimicrobial, antifungal, vasodilator, antitumour, antiviral, and anti-
Schistosoma sp. activity (Rollas & Kuçukguzel, 2007).  
The most recent researches on new compounds or drugs with schistosomicidal activity have 
been carried out with: a) inhibitors of cysteine protease, such as K11777, considered a 
powerful schistosomicide that reduces the pathogenesis of experimental schistosomiasis 
(Abdulla et al., 2007), b) RNAi, in the attempt to develop drugs or compounds that act as 
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enzyme silencers, e.g., the compound 4-phenyl-1,2,5-oxadiazole-3-carbonitrile-2-oxide, or 
furoxan, which acts on thioredoxin-glutathione reductase from S. mansoni (Kuntz et al., 2007, 
Sayed et al., 2008), c) trioxolanes or secondary ozonides (1, 2, 4-trioxolanes), which 
comprehend a class of synthetic endoperoxides that are cheap, easily synthesised, and 
similar to artemisinins, having activity on experimental infections with S. mansoni and S. 
japonicum (Caffrey, 2007, Xiao et al., 2007), d) mefloquine (antimalarial), which showed 
schistosomicidal activity against young and adult S. mansoni worms (Van Nassauw et al., 
2008, Keiser et al., 2009), e) arachidonic acid, which showed schistosomicidal properties 
against S. mansoni and S. haematobium (El Ridi et al., 2010), and f) miltefosine (anti-
leishmania), which reduced the parasite burden of mice infected with S. mansoni (Eissa et al., 
2011). At the present moment there are no clinical assays with these compounds. 
 Research with medicinal plants has gained prominence in recent years. According to WHO, 
this sort of research should be encouraged because traditional knowledge on biodiversity 
products is an important tool in the development of new pharmaceutical products intended 
to combat diseases that affect people in developing countries (WHO, 2002). 
Table 1 shows the drugs or compounds used up to this point in the treatment for human 
schistosomiasis. 
 
YEAR DRUG/COMPOUND SPECIES 
1918-1927 
 
Tartar Emetic – Antimony 
Compounds 
S. mansoni, S. haematobium, S. 
japonicum 
1920 Emetine and 2,3-
dehydroemetine 
S. japonicum 
1932 Lucanthone S. mansoni, S. haematobium 
1955 Metrifonate S. haematobium 
1964 Niridazole S. haematobium, S. mansoni, S. 
japonicum 
1965 Hycanthone S. mansoni, S. haematobium, S. 
rodhaini 
1969 Oxamniquine S. mansoni 
 
1975 
 
Praziquantel 
S. mansoni, S. japonicum, S. 
haematobium, S. intercalatum, S. 
mekongi 
1976 Amoscanate S. mansoni, S. japonicum 
1976 Oltipraz S. mansoni, S. haematobium, S. 
intercalatum 
1978 Benzodiazepines S. mansoni, S. haematobium 
1980 Artemisinin Derivatives S. mansoni, S. japonicum, S. 
Haematobium 
Table 1. Drugs and compounds with schistosomicidal activity that have already been tested 
in humans. Sources: Cioli et al., 1995, Ribeiro-dos-Santos et al., 2006. 
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3. Development of tolerance and resistance of Schistosoma mansoni to 
schistosomicidal drugs 
In the last 30 years the treatment for schistosomiasis has improved significantly in view of 
the introduction of praziquantel. Its oral administration in the dose of 40 to 60 mg/kg is 
efficient in reducing the morbidity, but the results of treatments with this drug have been 
less promising than expected. The reason is that cases of tolerance and resistance to the 
treatment for schistosomiasis have been reported for both oxamniquine and praziquantel 
(Parise-Filho & Silveira, 2001). 
Different strains of S. mansoni have been found susceptible to treatment, whether they come 
from the same region or from various individuals within the same community (Parise-Filho 
& Silverira, 2001).  
It has been known since the 1950’s that different strains of S. mansoni show different 
responses to treatments carried out with the same medication (Katz, 2008). At that time it 
was proved that the strain from Egypt was less susceptible to the treatment with  Miracil D 
than the strain from Liberia (Gonnert & Vogel, 1955).  
The first cases of resistance to schistosomicidal drugs were actually reported by Katz et al. in 
1973 in Brazil, and were related to oxamniquine and hycanthone. In 1978, strains tolerant 
and resistant to the treatment with praziquantel and oxamniquine were found in Brazil, 
Egypt, Kenya and Senegal (Dias et al., 1978, Stelma et al., 1995). 
In 1987, Kinoti suggested that S. mansoni could develop resistance to therapeutic doses of 
some drugs. At the time, the large variation of susceptibility to drugs among parasites, even 
among those from the same region, was already known. Studies conducted in Kenya, where 
the required doses of oxamniquine are higher than in Brazil, suggested the existence of 
tolerant worms even before the extensive use of chemotherapeutic drugs with 
schistosomicidal properties (Coles et al., 1987).  
In 1994, Fallon and Doenhoff provided an experimental demonstration that subtherapeutic 
doses of praziquantel, over many generations of parasites, resulted in worms less sensitive 
to the drug. Such resistance was in fact reported for the first time in Egypt and northern 
Senegal in 1995, when praziquantel was used in an attempt to control an epidemic of S. 
mansoni schistosomiasis (Fallon et al., 1995, Ismail et al., 1996).   
There has been much debate on the possibility of praziquantel becoming less effective due 
to its potential to generate resistance. Regarding what happened in Senegal, where the cure 
rates were low (between 18% and 39%, whilst the normal rates are 70% to 90%) (Cioli 2000, 
Grysseels et al., 2001), some authors suggest that the cure rates were aberrant (Doenhoff et 
al., 2009). Explanations for such rates included: Rapid reinfections after the treatment, 
presence of immature forms of the parasite during the treatment, and no prior exposition of 
the immunological system of the population to Schistosoma sp. (Cioli 2000, Grysseels et al., 
2001, Harnett & Kusel, 1986, Brindley & Sher, 1987, Doenhoff et al., 1987, Modha et al., 
1990). Some authors, however, point out that, since the cure rates in Senegaleses were 
atipically lower than expected, suspicions of a development of tolerance and resistance to 
treatment in that region can not be ignored (Danso-Appiah & de Vlas, 2002). Other authors 
consider that resistance becomes a problem when chemotherapy is massively used aiming 
to eradicate the disease only by medication, especially when cure rates do not reach 100%. 
The key in the process is the percentage of surviving worms that will contribute to the 
resistance of the next generation (Ismail et al., 1999, Liang et al., 2001), because such 
resistance would favour low cure rates and rapid reinfections after the treatment (Stelma et 
al., 1995).  
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Somehow, the extensive use of praziquantel has increased the concern for the development 
of Schistosoma sp. resistant to treatment (Fallon & Doenhoff, 1994). Since there are few other 
options regarding the treatment for schistosomiasis (Doenhoff et al., 2009), in particular for 
S. mansoni schistosomiasis, it is necessary to search for alternative drugs.  
The use of medicinal plants can be a very useful therapeutic alternative because the 
treatment is efficient and has low operational costs. Furthermore, such plants are easily 
found in Brazil, a country with a wide variety of native flora (Matos, 1994). 
4. Researches with medicinal plants to combat schistosomiasis  
Medicinal plants have been one of the most ancient forms of medicinal practice of 
humankind, having been used in the treatment of many diseases (Akerele, 1993). Based on 
information gathered along centuries, popular observations on the use and efficiency of 
medicinal plants have contributed significantly to the disclosure of their therapeutic 
properties (Maciel et al., 2002, WHO, 2003). 
It is estimated that only 17% of all the plants in the world have been studied in one way or 
another regarding their medicinal  use, in most cases, no deep analyses were carried out on 
their phytochemical and pharmacological properties. Many species are used empirically, 
with no scientific support on their efficiency and safety. These data show the enormous 
potential of plants for the discovery of new phytotherapeutic drugs (Cragg et al., 1999, 
Cordell & Colvard, 2005, Hamburger et al., 1991, Hostettmann, et al., 2003, Guerra, et al., 
1999). 
Medicinal plants and their derivatives were the basis of drug therapeutics until the middle 
of the 20th century, when chemical synthesis, initiated at the end of the 19th century, 
reached a new development stage (Silva & Carvalho, 2004).   
In the first half of the 20th century, studies with natural products were temporarily put 
aside on account of the emergence of new synthetic drugs, obtained from microorganisms 
that in most cases had no practical use in view of their high toxicity (Devienne et al., 2004). 
Furthermore, side effects caused by the use of those medicines were more and more 
frequently. There was no advantage in providing a fast and efficient treatment for a disease 
and then making another disease appear. Drugs had to be efficient and safe at the same 
time, as well as affordable (Oliveira & Akisue, 2000). 
In fact, there was a revolution in therapeutics at that moment, which led to the development 
of researches in the pharmacochemical industry with the purpose of synthesising active 
ingredients with less toxicity. Nevertheless, it did not take too long until the production of 
new drugs from totally synthetic substances stopped, in view of the high costs involved in 
their research and development (Devienne et al., 2004).   
It should be mentioned that the development of a new drug involves a complex process that 
may cost aroud 100 to 360 million dolars over a period of 10 to 12 years, representing about 
15% of the income of the pharmaceutical industry (Rates, 2001). On the other hand, the 
development of researches with medicinal plants has much lower costs (Ferreira, 2001). 
Other estimates show that the world market of pharmaceutical products generates 320 
billion dollars per year, of which 20 billion come from active substances derived from 
medicinal plants (Robbers et al., 1996). These facts have been promoting the interest in 
medicinal plants and the search for prototypes for the production of new drugs.  
A big limiting factor, though, is that most plants under use have not been described in 
official codes – pharmacopeia –, and there are not even studies on them.  In order to 
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introduce the use of medicinal plants in small production centres and prescription 
pharmacies, there must be investments in the elaboration of related official documents 
(Toledo et al., 2003). In this regard, the Brazilian government aproved the National Policy 
for Medicinal Plants and Phytotherapeutic Drugs (PNPMF) by decree n. 5,813 of June 22th, 
2006. This policy is an essential part of public policies for health, environment, and social 
and economic development, and is very important for the implementation of actions capable 
of promoting improvements in the life quality of Brazilian people (Ministério da Saúde, 
2009). 
The Brazilian flora consists of about 100,000 species, but only 8% of them had their chemical 
composition studied. In addition, many active ingredients are still unknown, and it is 
estimated that only 1,100 species have been examined regarding their therapeutic properties 
(Anthony et al., 2005, Reis et al., 2007, Varanda, 2006).  
According to Rodrigues and West (1995), the study of medicinal plants in tropical countries 
is very interesting because such species have 3 to 4 times more chemical compounds than 
plants found in temperate zones. 
From the pharmacological viewpoint, it is absolutely necessary that the activities of 
ingredients or substances isolated from plants be evaluated in preclinical assays. 
Experimental models are used in the analysis of antiparasitic, anti-inflammatory, 
antimicrobial, analgesic, antitumour and anticonvulsant effects, among others, as well as in 
toxicologic evaluation (acute and chronic toxicity), primary and cumulative dermal 
irritation, ocular irritation, cutaneous sensitivity, and phototoxicity. The development of 
such studies allows us to reach the end of the multidisciplinary cycle in the research with 
medicinal plants (Foglio et al., 2006). 
According to Githori et al. (2006), plants with antiparasitic activity usually contain saponins, 
alkaloids, non-protein amino acids, tannins, polyphenols, lignins, terpenes, lactones, 
glycosides, and phenolic compounds. As a result, many species can be candidates for 
thorough studies concerning this function. Table 2 describes some species of medicinal 
plants with confirmed schistosomicidal activities.   
Among the several medicinal plants cultivated in Brazil, in this chapter we will focus on 
four species that for decades have been submitted to biological and pharmacological studies, 
in view of the fact that their active ingredients have proven effective to combat many 
diseases. In recent years our research group started a multidisciplinary project intending to 
carry out in vitro screenings of extracts and fractions from these plants against experimental 
infections in S. mansoni. The best results were found for Artemisia annua, Baccharis trimera, 
Cordia verbenacea and Phyllanthus amarus.  
 
Scientific 
Name 
Used Part of 
the Plant 
Extract/ 
Compound 
Species Observations References 
Abrus 
precatorius 
Stem and Roots
Aqueous 
Extract 
S. mansoni 
In Vitro Test -  
Schistosomulum
Molgaard et al., 
2001 
Ozoroa insignis 
Leaves and 
Bark of the 
Roots 
Aqueous 
Extract 
S. mansoni 
In Vitro Test -   
Schistosomulum
Molgaard et al., 
2001 
Elephantorrhiza 
goetzei 
Barks of the 
Stem 
Aqueous 
Extract 
S. mansoni 
In Vitro Test - 
Schistosomulum
Molgaard et al., 
2001 
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Scientific 
Name 
Used Part of 
the Plant 
Extract/ 
Compound 
Species Observations References 
Commiphora 
molmol 
Stem Myrrh 
S. mansoni e S. 
haematobium 
_ 
Sheir et al., 
2001, El Baz et 
al., 2003, 
Barakat et al., 
2005 
Nigella sativa Seeds 
Oil, Aqueous, 
Ethanolic and 
Chloroform 
Extracts 
S. mansoni 
In Vivo Test with 
Egyptian strain 
(Oil), In Vitro 
Test with 
Miracidia, 
Cercariae and 
Adults (Extracts)
Mahmoud et 
al., 2002,  
Mohamed et 
al., 2005,  El-
Shenawy et al., 
2008 
Allium sativum 
Crushed Scale 
Leaves 
Aqueous 
Extract, Dry 
Crude Extract 
S. mansoni 
Egyptian strain, 
In Vivo Test 
Riad et al., 
2007, Mantawy 
et al., 2011 
Clerodendrum 
umbellatum 
Leaves 
Aqueous 
Extract 
S. mansoni 
Cameroonian 
strain, In Vivo 
Test 
Jatsa et al., 2009 
Curcuma longa _ Curcumin S. mansoni LE strain, 
Magalhães et 
al., 2009 
Zanthoxylum 
naranjillo 
Leaves 
Fraction of 
Ethyl  Acetate 
S. mansoni In Vitro Test 
Braguine et al., 
2009 
Dryopteris sp. Rhizome Phloroglucinol S. mansoni LE strain 
Magalhães et 
al., 2010 
Piper 
tuberculatum 
Inflorescence Piplartine S. mansoni 
BH strain, In 
Vitro Test 
Moraes et al., 
2010 
Baccharis 
dracunculifolia 
Leaves Essential Oil S. mansoni 
Native of Brazil, 
LE strain, In 
Vitro Tests 
Parreira et al., 
2010 
Cratylia mollis Seeds Cramoll 1,4 S. mansoni 
Native of Brazil, 
BH strain, In 
Vivo Test 
Melo et al., 
2011 
Zingiber 
officinale 
Rhizome 
Aqueous 
Extract 
S. mansoni In Vivo Test 
Mostafa et al., 
2011 
Ageratum 
conyzoides L 
Leaves Essential Oil S. mansoni 
LE strain, In 
Vitro Test 
Melo et al., 
2011 
Allium cepa Scale Leaves 
Dry Crude 
Extract 
S. mansoni 
Egyptian strain, 
In Vivo Test 
Mantawy et al., 
2011 
Table 2. Medicinal plants with attested schistosomicidal activity.  
4.1 Bioassays – In vitro tests 
Given the global interest in exploring anthelmintic activities of plants and their products, 
there is a growing interest in finding the best way to evaluate their bioactivity. Time and 
financial costs involved in tests require the screening techniques to be sensitive, preferably 
low-cost and reproducible (Jackson & Coop, 2000).  
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In general, plants contain a large number of secondary metabolites, which can act 
individually or in combination to produce direct or indirect effects on the parasites. 
Accordingly, the first screening stage should reduce the number of substances for the 
following stage, which consists of the discovery of active compounds, a complex and 
expensive process. That stage is important because the understanding of the nature of the 
active compounds, their action mode and their targets in the parasites is what will 
determine its applicability (Jackson & Coop, 2000, Athanasiadou et al., 2001, Athanasiadou 
& Kyriazkis, 2004).  
In vitro assays are used for screening. In vitro tests are a primary screening, considering that 
a large number of plants can be examined to demonstrate their potential effect (Cabaret et 
al., 2002, Athanasiadou & Kyriazakis, 2004, Ketzis et al., 2006). 
During an in vitro test for helminths, the parameter analysed is the viability of adult worms. 
Motility, oviposition, tegument changes, changes in internal organs, mating, and especially 
the mortality of such worms can all be observed. 
4.2 In vitro tests with Brazilian medicinal plants to combat S. mansoni 
schistosomiasis 
The plants used in the assays were cultivated and collected at the Experimental Field of the 
Chemical, Biological and Agricultural Pluridisciplinary Research Centre (CPQBA) – 
Unicamp – Campinas (-22°54'20''/-47°03'39'') – São Paulo – Brazil. In order to obtain the 
extracts, fractions and isolated compounds the aerial parts of the plants were used.  In order 
to carry out the in vitro tests, mated males and females of S. mansoni were used. They were 
kept in RPMI-1640 medium, along with penicillin/streptomycin, in a CO2 oven at 5% and 
temperature of 37ºC. The results of these tests showed schistosomicidal activity in the 
samples during the observation period, which lasted 72 hours. 
4.2.1 Artemisia annua L. 
(Allegretti, S. M., 2011) 
Artemisia annua L (Asteraceae), known as Artemisia or Qinghaosu, is indigenous to China 
and has been used for centuries in Chinese medicine in the treatment for fever crisis (Figure 
2). This species was introduced and naturalised in several countries in Europe, northern and 
central Asia, India, Australia, northern Africa, and South and North Americas (Klayman, 
1993, WHO, 2006). 
Artemisinin and its derivatives are compounds with low toxicity, no mutagenic effects, and 
good tolerance, being a primary option in antimalarian therapy in many tropical and 
subtropical countries, such as China, Thailand, Cambodia, Laos, Vietnam, Brazil, Zaire, 
Gabon, Madagascar, Ghana, among others (Guo et al., 1998, Xiao, 2002, Jiraungkoorskul et 
al., 2006). Such compounds have also shown schistosomicidal activity (Jiraungkoorskul et 
al., 2006, Shaohong et al., 2006, Mitsui et al., 2008). 
Our research group has compared the activity of artemisinin and artesunic acid in adult 
couples of the BH strain of S. mansoni, native of Belo Horizonte (-19°55'15''/-43°56'16''), 
Minas Gerais, Brazil, by means of in vitro tests. Twenty-two hours after the addition of the 
two compounds, death was observed in all concentrations tested.  Three replications of the 
experiment were carried out for each concentration. Worms of negative control groups, i.e., 
with no addition of compounds or drugs, stayed alive until the end of the experiment. Table 
3 shows the mortality of worms within the observation period.  
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Fig. 2. Artemisia annua L. cultivated in the Experimental Field of CPQBA – Unicamp, 2011. 
 
Time when the mortality rate reached 100% 
 C1(1500µg/mL) C2 (1000µg/mL) C3(500µg/mL) 
Artesunic acid 5th hour 5th hour 22nd hour 
Artemisinin 20th hour 20th hour 22nd hour 
Praziquantel 20th hour 20th hour 22nd hour 
Table 3. Activity of artesunic acid, artemisinin and praziquantel in relation to the mortality 
of S. mansoni. Concentrations: C1 = 1500µg/mL, C2 = 1000µg/mL, C3 = 500µg/mL. 
It has already been proven that both artemisinin and artesunic acid act in different ways on 
strains of S. mansoni, such as LE, Liberian and Puerto Rico. Tests comparing strains of S. 
mansoni with artesunic acid are still rare in the literature, but in in vivo studies we notice that 
different strains respond differently to the treatment.  
All these strains showed differences in the percentage of worm distribution in the hepatic 
portal system, mortality and oogram change (Araújo et al. 1999, Utzinger et al., 2002, Lu et 
al., 2004, 2006). Such differences between strains of S.mansoni in the vertebrate host are 
considered a manifestation of the genotypic expression of the trematode (Yoshioka et al. 
2002). For the comparison between the activity of artesunic acid and artemisinin against the 
BH and SJ strains of S. mansoni (the latter being native of São José dos Campos, -23°10'46''/-
45°53'13'', São Paulo, Brazil), experiments in Swiss mice were carried out with further 
treatments on different days, i.e., on the 30th and 45th days after the infection. Concentrations 
of 300 and 500 mg/kg were orally administered, divided along five consecutive days. 
Fifteen days after the administration of the last concentration, the reduction rates of the BH 
strain worms in the hepatic portal system of mice were compared with negative control 
group (not treated), and the result was 49% of worm reduction for artesunic acid (with 300 
and 500 mg/kg) in treatment carried out after 30 days of infection. However, no reduction 
was found for artemisinin in neither concentration, tested under the same conditions. In 
treatments carried out after 45 days of infection, there was worm reduction of 41% with the 
use of artesunic acid, 500 mg/kg, but no reduction was found in the group treated with 
artemisinin in the same concentration and on the same day.   
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In regard to the same strain, eggs eliminated in the feces were reduced at even 100% with 
the use of artesunic acid, 300 mg/kg, administered after 30 days of infection, but no similar 
results were found in similar treatments with artemisinin. Oviposition reduction of 100% 
was also observed with artesunic acid, in treatment carried out on the 45th day of infection in 
both concentrations, whereas artemisinin reached 81% of oviposition reduction on the same 
day, in the 300mg/kg concentration. 
Better results were achieved with the SJ strain concerning worm reduction: maximum of 
49% in treatments with 500 mg/kg of artesunic acid, administered after 30 days of infection, 
and 30% with artemisinin, in the same concentration and period. In treatments carried out 
after 45 days of infection worm reduction reached 76% with 300 mg/kg of artesunic acid, 
whereas no reduction was found with the use of artemisinin in the same period in either 
concentration. 
Regarding oviposition, 500 mg/kg of artesunic acid provided a reduction of 99% when 
administered after 30 days of infection, whilst the same concentration of artemisinin 
provided a reduction of 89% in the same period. In treatments carried out with 500 mg/kg 
of artesunic acid after 45 dias, the reduction rate reached 98%, but no reduction was found 
in treatments with artemisinin. 
These results showed that artesunic acid had better activity regarding the parameters in 
question (worm and oviposition reduction) for both strains under study. In addition, the use 
of artesunic acid showed no significant difference between these parameters in treatments 
carried on the 30th and 45th days of infection for both strains. Regarding artemisinin, we 
could observe that the SJ strain of S. mansoni showed higher worm and oviposition 
reduction rates than the BH strain, particularly in treatments after 30 days of infection, 
which demonstrates the difference between the strains in what refers to treatment response.  
4.2.2 Baccharis trimera (Less) DC. 
(Oliveira, R. N., 2011) 
Baccharis trimera (Less) DC. (Figure 3) is a plant native of South and Southeast Brazil, also 
found in Argentina, Bolivia, Paraguay and Uruguay (Bona et al., 2005, Lorenzi & Matos 
2002). This species belongs to the family Asteraceae, which includes around 1,100 genera 
and 25,000 species distributed worldwide (Moreira et al., 2003). Plants of this family are 
extensively studied regarding their chemical composition and biological activity because of 
their outstanding  allelopathic, anti-inflammatory, antimutagenic and antimicrobial effects. 
Some of these species have even made possible the development of new drugs and 
insecticides, among other products (Verdi et al., 2005).  
The genus Baccharis has more than 500 species widely distributed in Brazil, Colombia, Chile, 
Argentina and Mexico (Lorenzi & Matos, 2002). The phytochemistry of this genus has been 
studied since the beginning of the last century, and so far more than 150 compounds have 
been isolated and identified (Abad et al., 1999). Flavonoids and terpenoids, such as 
monoterpenes, sesquiterpenes, diterpenes and triterpenes, are the most frequent compounds 
(Moreira et al., 2003, Verdi et al., 2005).   
The name Baccharis (Bakkharis) comes from Greek and is an old denomination for some 
shrub-like plants (Kissmann & Groth, 1999). This plant is popularly known as carqueja and 
its most distinct characteristic is the presence of cladophylls, which replace leaves as the 
main photosynthetic organs of the plant, as there are no leaves or they are extremely 
reduced, with limited physiological function (Barroso, 1976). Carqueja was first used in folk 
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medicine in Brazil by Correa in 1931, who described the use of the infusion of its aerial parts 
in the treatment for female sterility and male impotence (Lorenzi & Matos, 2002). Nowadays 
B. trimera is mostly consumed in teas, being extensively used in folk medicine on account of 
its diuretic properties and in the treatment for gastrointestinal and hepatic diseases, as well 
as for angina, poor blood circulation, diabetes and inflammatory processes (Corrêa, 1984, 
Moreira et al., 2003, Souza et al., 1991). 
 
 
Fig. 3. Baccharis trimera (Less) DC. A. Seedling, B. Inflorescence. Source: Experimental Field 
of CPQBA- Unicamp, 2011. 
From the species B. trimera a series of flavonoids have already been isolated, including 
eupatorin, eupatrin, cirsimaritin, rutin, cirsiliol, genkwanin, eriodictyol, kaempferol, 
quercetin, luteolin, nepetin, apigenin e hispidulin, 5-OH- 6,7,3,4-OMe flavone, 5,6-OH-
7,3’,4’-OMe flavone and 5,7,3,4-OH-3-O-rhamnosyl-glycosyl flavone (Borella et al., 2006, 
Soicke et al., 1987, Verdi et al., 2005). 
Several biological studies were conducted intending to confirm the pharmacological 
properties of B. trimera. For instance, the decoction of this plant showed antimicrobial 
activity (bacteriostatic and bactericidal) in both Gram-positive and Gram-negative bacteria 
through in vitro assays, supporting its use as antiseptic and disinfectant (Avancini et al., 
2000). 
Among the studies conducted so far we can point out the works carried out with the 
aqueous extract from B. trimera. This extract showed activity on the reduction of gastric 
lesions induced by stress in mice (Gamberini et al., 1991), on the relaxation of the intestinal 
smooth musculature in rats (Torres et al., 2003), on the reduction of the blood glucose level 
in mice, indicating a potential antidiabetic activity (Oliveira et al., 2005), in addition to anti-
inflammatory and immunomodulatory effects (Paul et al., 2009). 
Hydroalcoholic extract showed antioxidant activity through in vitro and in vivo tests in 
neutrophils of mice (Pádua et al., 2010). Another in vitro test with the same extract showed 
antiparasitic activity against amastigote and promastigote forms of Leishimania (L) 
amazoniesis and epimastigote forms of Trypanosoma cruzi (Luize et al., 2005).  
It was also reported that the methanolic extract from B. trimera showed antimutagenic 
activity through in vitro assays (Nakasugi & Komai, 1998). 
The molluscicidal activity in Biomphalaria glabrata (Pulmonata: Planorbidea) was studied 
from a diterpenic lactone and a flavone isolated from B. trimera (Santos-Filho et al., 1980).   
The compound neoclerodane diterpene showed inhibitory action on metalloproteases 
present in the venom of Bothrops sp., which demonstrates the antihemorrhagic, 
antiproteolytic, antimyotoxic and antiedematogenic properties of B. trimera (Januário et al., 
2004). 
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Polyphenolic compounds isolated from B. trimera, B.crispa and B.usterii by means of aqueous 
extract showed anti-inflammatory and antioxidant activities (Simões, et al., 2005). 
In addition to the studies mentioned here, other biological activities B. trimera have been 
demonstrated, as shortly shown in Table 4. 
 
 
Activity Extract/ Compound References 
 
Molluscicidal 
 
 
Antimutagenic 
 
Diterpene Lactone and 
Flavone 
 
Methanolic Extract 
 
 
Santos-Filho et al., 1980 
 
 
 
Nakasugi & Komai, 1998 
 
Disinfectant and     
Antiseptic 
 
Decoction 
 
Avancini et al.,2000 
 
Antiproteolytic, 
Antihemorrhagic 
 
Chloroform: Methanol 
 
 
Januário et al., 2004 
 
 
Antiparasitic, Antiulcer, 
Antioxidant, Hepatorenal 
Hydroalcoholic Extract 
 
Dias et al., 2009, Grance et 
al., 2009, Luize et al., 2005, 
Pádua et al., 2010 
Hypoglycemic, Anti-
inflammatory, 
Immunomodulatory, 
Genotoxicity, 
Antigenotoxicity 
 
Aqueous Extract 
 
Barbosa-Filho et al., 2005, 
Leite et al., 2007, Paul et 
al.,2009, Rodrigues et al., 
2009 
 
 
Table 4. Major biological activities of Baccharis trimera described in the literature. 
Among the several biological activities of B. trimera mentioned in the literature, we can 
highlight its anti-inflammatory and hepatorenal activities, which raised the interest of our 
research group in studying this plant in the treatment for S. mansoni schistosomiasis because 
granulomatous inflammatory responses, the main pathology of the disease, affect many 
organs, especially the liver. Therefore, we have been carrying out screening of raw extracts 
and fractions from this plant by in vitro assays.  
Crude dichloromethane and hydroalcoholic extracts were used so that the schistosomicidal 
activity of B. trimera on the BH strain of S. mansoni could be evaluated. Different 
concentrations – C1 = 130µg/mL, C2 = 91µg/mL, C3 = 48µg/mL and C4 = 24µg/mL – of the 
extracts were tested on couples of adult worms, five replications being performed for each 
concentration. At the end of the experiment, i.e., 72 hours later, the following mortality rates 
were observed: 
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Dichloromethane 
Extract 
Hydroalcoholic 
Extract 
Praziquantel Control 
C1 (130 µg/mL) 100% 70% 100% - 
C2 (91 µg/mL) 100% 70% 100% - 
C3 (48 µg/mL) 100% 50% 70% - 
C4 (24µg/mL) 90% 30% 60% - 
Table 5. Evaluation of the mortality of couples of Schistosoma mansoni submitted to different 
concentrations of Baccharis trimera.  Control: Negative Control Group, with no addition of 
any extract or drug for 72 hours. 
Considering these results, we conclude that the dichloromethane extract showed better 
activity in comparison with the hydroalcoholic one and that male specimens of S. mansoni 
were more susceptible to the activity of the former. Therefore, it can be accepted that B. 
trimera has active compounds against the BH strain of S. mansoni.    
The effect of the observation period on the mortality of the worms was also analysed. The 
crude dichloromethane extract proved to be more effective, as the concentrations C1 
(130µg/mL) and C2 (91µg/mL) caused the death of 100% of the worms in an observation 
period of 48 hours (Figure 4).   
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Fig. 4. Activity of the crude dichloromethane and hydroalcoholic extracts from Baccharis 
trimera and praziquantel on the viability of male and female Schistosoma mansoni worms in 
relation to the observation period of 72 hours. 
4.2.3 Cordia verbenacea DC. 
(Frezza, T.F., 2011) 
Cordia verbenacea DC (also referred to as Cordia salicina, Cordia curassavica, Cordia 
cylindristachia, Lithocardium fresenii, Lithocardium salicinum and Lithocardium verbaceum) is a 
medicinal plant native of Brazil, commonly known as maggy plant (erva-baleeira or salicina in 
Brazilian Portuguese). It belongs to the family Boraginaceae, widely distributed along the 
Brazilian shore, but found mainly from the shore of São Paulo to Santa Catarina (Carvalho et 
al., 2004). Species of the genus Cordia are found in tropical and subtropical regions in Asia, 
southern Africa, Australia, Guyana and South America in general (Ficarra et al., 1995). 
Figure 5 shows a specimen of C. verbenacea. 
 
 
Fig. 5. Cordia verbenacea. A. Leaves, B. Inflorescence. Source: Experimental Field of CPQBA – 
Unicamp, 2011. 
Several compounds are found in the aerial parts of C. verbenacea, including tannins, 
flavonoids and essential oils. Such parts have been used in folk medicine in the form of 
alcoholic extracts and infusions in view of their antiulcer, antimicrobial, anti-inflammatory 
and antirheumatic activities, as well as their tonic and analgesic properties (Carvalho et al., 
2004, Passos et al., 2007). Since a variety of chemical groups found in extracts from C. 
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verbenacea allegedly have biological activities, this plant is an important material for 
pharmaceutical investigation (Michielin et al., 2009). In recent years, the activities of 
different extracts from C. verbenacea have been extensively discussed. 
Preclinical studies have shown that the hydroalcoholic extract from C. verbenacea has anti-
inflammatory activity, either by oral or topical administration, and protects the gastric 
mucosa (Sertie et al., 2005, Roldão et al., 2008). It also has antioxidant activity (Michielin et 
al, 2011) and inhibits the growth of Gram-positive and Gram-negative bacteria (Meccia et al., 
2009, Michielin et al., 2009).  
Its essential oil has antimicrobial activity along with inhibitory activity against the growth of 
some Gram-positive bacteria in in vitro cultures (Carvalho et al., 2004), as well as antialergic 
activity (Passos et al., 2007) and larvicidal activity against Aedes aegypti (Santos et al., 2006). 
The bioguided isolation of this oil led to the identification of other two active compounds 
with anti-inflammatory activity, namely alpha-humulene and trans-caryophylllene (Passos 
et al., 2007). 
The anti-inflammatory activity of the essential oil made it possible to develop the first 
Brazilian phytodrug, Acheflan, an anti-inflammatory drug of topical use.   
Different activities have also been reported for other extracts, such as the methanolic extract, 
which presents effects on oedema formation and reduction of myotoxicity induced by the 
venom of Bothrops jararacussu (Ticli et al., 2005), and the dichloromethane extract, which has 
shown  antiedematogenic activity in in vivo assays (Bayeux et al., 2002). The antiparasitic 
activity of methanolic extracts from C. verbenacea has already been tested against Leishmania 
sp. (Braga et al., 2006) and is currently studied by our research group against S. mansoni. C. 
verbenacea was chosen by our research group for in vitro studies because of its anti-
inflammatory properties.  
Table 6 provides a summary of the actions of extracts or compounds from C. verbenacea. 
 
Activity Extract/ Compound Reference 
 
Anti-inflammatory, 
Protection of the Gastric 
Mucosa, Antiulcer, 
Antioxidant, Antimicrobial 
 
Hydroalcoholic Extract 
 
 
Sertié et al., 1990, Sertié et 
al., 2005, Passos et al., 2007, 
Roldão et al., 2008, Meccia 
et al., 2009, 
Michielin et al., 2009, 
Michielin et al., 2011 
 
Anti-inflammatory, 
Antimicrobial, Antialergic, 
Larvicidal 
 
Essential Oil 
 
De-Carvalho et al., 2004, 
Santos et al., 2006, Passos 
et al., 2007 
 
Reduction of Myotoxicity, 
Antiparasitic (Leishmania 
sp.) 
 
Methanolic Extract 
 
Ticli et al., 2005,Braga et 
al.,2007 
   
Antiedematogenic Dichloromethane Extract 
Bayeux et al., 2002 
 
Table 6. Major biological activities of Cordia verbenacea described in the literature. 
www.intechopen.com
 Schistosomiasis 
 
46
The aqueous fraction, organic fraction (obtained from the ethanolic extract) and essential oil 
were used for the analysis of the in vitro schistosomicidal activity of C. verbenacea against the 
BH strain of S. mansoni. Different concentrations of the extracts were tested against couples 
of adult worms, with five replications carried out for each concentration. At the end of the 
experiment (72 hours), the following mortality rates were observed: 
 
 
 
Essential Oil Aqueous 
Fraction 
Organic 
Fraction 
Praziquantel Control 
C1 (400 µg/mL) 30% 30% 100% 100% - 
C2 (200 µg/mL) 30% 30% 100% 100% - 
C3 (100 µg/mL) 30% 20% 90% 90% - 
C4 (50 µg/mL) 20% 10% 60% 90% - 
Table 7. Evaluation of the mortality of couples of Schistosoma mansoni submitted to different 
concentrations of C. verbenacea. Control: Negative Group Control, with no addition of any 
extract or drug for 72 hours.  
The effect of the observation period on the mortality of the worms was also analysed. We 
consider that the best extract from C. verbenacea was the one that in 24 hours was able to 
eliminate more worms with higher concentrations (Figure 6). 
 
 
 
 
 
www.intechopen.com
 The Use of Brazilian Medicinal Plants to Combat Schistosoma mansoni 
 
47 
 
 
 
 
 
 
 
Fig. 6. Activity of the aqueous fraction, essential oil and organic fraction from Cordia 
verbenacea and praziquantel on the viability of male and female Schistosoma mansoni worms 
in relation to the observation period of 72 hours. 
4.2.4 Phyllanthus amarus L. 
(Oliveira, C.N.F., 2011) 
Phyllanthus amarus belongs to the family Euphorbiaceae (Calixto et al., 1998), which 
comprises 317 genera and 8,000 species, grouped into 49 tribes and 5 subfamilies (Torres et 
al., 2003). Plants belonging to the genus Phyllanthus are widely distributed in most tropical 
and subtropical countries (in both hemispheres) and include between 550 and 750 species. It 
is believed that there are about 200 species of this genus distributed throughout the 
Americas, being mostly found in Caribe and Brazil (Calixto et al., 1998, Torres et al., 2003). 
The name Phyllanthus comes from Greek, phyllon meaning ‘leaf’ and anthos meaning ‘flower’, 
a reference to the flowers produced in branches, resembling compound flowers (Figure 7) 
(Torres et al., 2003). 
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Fig. 7. A – Specimen of Phyllanthus amarus, B. Amplified image. Source: Experimental Field 
of CPQBA – Unicamp, 2011. 
In Brazil, plants of the genus Phyllanthus are popularly known as stone-breaker (quebra-
pedra, arrebenta-pedra or erva-pombinha in Brazilian Portuguese) and are recognised in folk 
medicine in Brazil and other countries for their diuretic properties. They are used in the 
treatment for kidney and bladder disorders, helping in the passage of renal calculi, and also 
act on intestinal infections, diabetes and hepatitis B (Calixto et al., 1998, Jain et al., 2003, 
Khatoon et al., 2006, Rajakannan et al., 2003, Torres et al., 2003).  
A large variety of species of plants belonging to this genus have been phytochemically and 
pharmacologically investigated and many molecules have been isolated and identified. 
Among all the species studied, P. amarus has been given special attention. Although many of 
its compounds are chemically known, the properties of most of these compounds remain 
unknown. Some pharmacological activities of P. amarus have already been confirmed by 
scientific studies, such as: (1) treatment for hepatitis B, by suppression of the replication of 
the virus (Thyagarajan et al., 1988), (2) hepatoprotective effect against actions of 
paracetamol, carbon tetrachloride (CCl4), galactosamine and alcohol (Krithika et al., 2009, 
Pramyothin et al., 2007) – phyllanthin and hypophyllanthin, which are lignans present in P. 
amarus, are described as having hepatocyte-protective action against carbon tetrachloride 
(Khatoon et al., 2006), (3) aqueous extracts from P. amarus have shown a strong inhibitory 
action against hepatic carcinoma (Rajeshkumar & Kuttan, 2000), (4) possible antispasmodic 
effects of the extract on the smooth musculature have been reported because they contribute 
to the effects on the renal calculi (Kassuya et al., 2003), (5) antibacterial activity of the 
ethanolic extract (Kloucek et al., 2005), (6) potential anti-inflammatory activity of both the 
hexane extract and the chemical fraction rich in lignans, obtained from the leaves of P. 
amarus. The anti-inflammatory activity of lignans was evaluated and it was noticed that 
nirantin is the most active substance of this fraction. Moreover, an analgesic effect  has also 
been reported (Kassuya et al,. 2005, Kassuya et al., 2006), (7) inhibition of gastric lesions with 
the use of the methanolic extract from P. amarus (Raphael & Kuttan, 2003), (8) in vitro and in 
vivo inhibition of the replication of the human immunodeficiency virus (HIV) (Notka et al., 
2004), (9) hypoglycemic activity, useful in the treatment for diabetes mellitus, with the 
methanolic extract (Raphael et al., 2002), (10) antiplasmodial activity, demonstrated by the 
use of the aqueous extract from the leaves and stem of the plant against Plasmodium berghei 
(Dapper et al., 2007), (11) studies on the radioprotective properties of polyphenols (tannins 
and flavonoids) isolated from P. amarus and described by Londhe et al (2009) showed that of 
all the tested compounds ellagitannin had the best activity, (12) potential antioxidant 
activity of the aqueous extract in rats (Karuna et al., 2009).  
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Considering the studies carried out so far, briefly presented in Table 8, the interest for plants 
of the genus Phyllanthus has increased significantly, particularly in regard to their 
therapeutic potential against many diseases. Many reasons have contributed to this interest, 
including: their wide distribution in many tropical and subtropical countries, the large 
number of species in this genus, their extensive therapeutic use in folk medicine, and the 
great variety of secondary metabolites present in these plants (Calixto et al., 1998). 
 
Activity Extract/ Compound Reference 
Inhibition of gastric lesions; 
Hypoglycemic 
Methanolic Extract 
Raphael & Kuttan, 2003; 
Raphael et al., 2002 
Hepatoprotective Crude Extract; Phyllantin 
Pramyothin et al., 2007; 
Krithika et al., 2009 
Protection of the hepatocytes 
against  carbon tetrachloride 
(CCl4) 
Phyllantin and 
Hipophyllantin, which are 
lignans present in the plant 
Khatoon et al., 2006 
Inhibition of hepatic 
carcinoma; Supression of the 
replication of the virus of 
hepatitis B; 
Hepatoprotective; 
Antisplasmodial 
(Plasmodium berghei);  
Antioxidant 
Aqueous Extract 
Rajeshkumar & Kuttan, 
2000; Thyagarajan et al., 
1988; Pramyothin et al., 
2007; Dapper et al., 2007 ; 
Karuna et al., 2009 
In vitro and in vivo inhibitory 
effect of HIV; Antibacterial 
Ethanolic Extract 
Notka et al., 2004; Kloucek 
et al., 2005 
Anti-inflammatory; 
Analgesic 
Hexane Extract and 
Chemical Fraction rich in 
lignans, obtained from the 
leaves of P. amarus 
Kassuya et al., 2005; 
Kassuya et al., 2006 
Radioprotective Properties 
Ellagitannin, isolated 
compound 
Londhe et al., 2009 
Table 8. Major biological activities of Phyllanthus amarus described in the literature.  
There have been no reports of studies on P. amarus applied to the treatment for S. mansoni 
schistosomiasis. Nevertheless, records of anti-inflammatory and hepatoprotective activities 
of this plant have been found, which has led to the selection of the plant for this study, as 
the main pathogeny of schistosomiasis is the granulomatous inflammatory response. 
 An in vitro study with the ethanolic extract and fractions obtained from P. amarus was 
carried out so that the schistosomicidal effect of this plant against the BH strain of S. mansoni 
could be verified. Four concentrations – C1= 200µg/mL, C2 = 100µg/mL, C3 = 50µg/mL e 
C4 = 25µg/mL - of the extracts were tested against couples of adult worms, with five 
replications carried out for each concentration. At the end of the experiment (72 hours), the 
mortalities observed are the ones indicated in Table 9.  
www.intechopen.com
 Schistosomiasis 
 
50
 
 
 Ethanolic 
Extract 
Fraction 
1 
Fraction 
2 
Fraction 
3 
Fraction 
4 
Praziquantel Control 
C1 
(200 µg/mL) 
100% 100% 90% 100% 100% 100% - 
C2 
(100 µg/mL) 
100% 100% 40% 100% 90% 60% - 
C3 
(50 µg/mL) 
40% 40% - 100% 30% 80% - 
C4 
(25 µg/mL) 
20% 20% 10% 100% 20% 60% - 
 
Table 9. Evaluation of the mortality of couples of Schistosoma mansoni submitted to different 
concentrations of Phyllanthus amarus. Control: Negative Group Control, with no addition of 
any extract or drug for 72 hours.  
These results show that the fractions had better activity against the worms, taking into 
account the ones that managed to eliminate them more quickly.   
The effect of the observation period on the mortality of the worms was also analysed. We 
consider that fractions 1 and 4 in C1 (200µg/mL) and fraction 3 in C1, C2 (100µg/mL) and 
C3 (50µg/mL) were more effective because after 24 hours of observation 100% of the worms 
were dead (Figure 8). 
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Fig. 8. Activity of the crude ethanolic extract and fractions 1, 2, 3 and 4 of Phyllanthus amarus 
and praziquantel on the viability of male and female Schistosoma mansoni worms in relation 
to the observation period of 72 hours. 
As seen in the results of the in vitro tests, fraction 3 isolated from the crude ethanolic extract 
from P. amarus showed the best schistosomicidal activity. 
5. Conclusion 
We can conclude that the species of plants studied by our research group have 
schistosomicidal activity against S. mansoni. It is also worth pointing out that:  
- The higher activity of artesunic acid in both in vitro and in vivo assays in comparison 
with artemisinin, with higher worm and oviposition reduction rates for both strains 
studied, which demonstrates that the different responses to the treatment by the two 
strains have not prevented the compound from working against them, 
- In vitro assays with B. trimera showed better schistosomicidal activity for the crude 
dichloromethane extract, resulting in the mortality rate of 100% in the three 
concentrations tested, moreover, it was possible to notice that male S. mansoni worms 
were more susceptible to the action of this extract,  
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- The higher activity of the organic fraction from C. verbenacea in in vitro tests on the 
viability of the worms, killing a larger amount in less time in comparison with other 
extracts, also showing higher activity against male worms, 
- The results of the in vitro tests carried out with P. amarus, which demonstrated that 
fraction 3 isolated from the crude ethanolic extract had better schistosomicidal activity 
because the mortality rate was 100% in all concentrations tested. 
Considering the good results obtained so far, our research group will continue the chemical 
biomonitoring study by means of activity assays, aiming to isolate and identify fractions and 
compounds responsible for schistosomicidal activities shown by the medicinal plants under 
investigation. 
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